NeuDirection Limited Celebrates NMPA Clinical Trial Approval for Neu-001 to Treat Amblyopia
NeuDirection Limited is pleased to announce Neu-001 for Injection has received Investigational New Drug (IND)…
CRMH Hosts International Symposium on Advancing Amblyopia Therapies in Hong Kong
The symposium “Advancing Amblyopia Care: Innovations in Clinical Trials and Multisensory Approaches in Neuroscience and…
Neu-001 for Amblyopia Treatment Secures FDA Approval for Clinical Trials
Our first pipeline Neu-001,Neu-001, an innovative first-in-class small-molecule drug for treating amblyopia (commonly known as…